ANVISA Risk-Based Inspection: What You Need to Know
Learn how ANVISA's Risk-Based Inspection enhances drug safety and compliance, streamlining processes for pharmaceutical manufacturers and protecting patient health.
Quick Answer
Learn how ANVISA's Risk-Based Inspection enhances drug safety and compliance, streamlining processes for pharmaceutical manufacturers and protecting patient health.
Key Questions
- What is ANVISA RDC 982/2025 and when does it take effect?
- How does the risk-based inspection system reduce regulatory burden?
- Which international standards does ANVISA's new system align with?
- What products are covered under RDC 982/2025?
- How can manufacturers prepare for risk-based inspections?
Brazil's health regulator ANVISA implemented RDC 982/2025 on July 29, 2025, replacing traditional uniform GMP inspections with a risk-based certification system. The new framework aligns with ICH Q9 Quality Risk Management and PIC/S standards, enabling more efficient resource allocation while maintaining stringent patient safety standards.
Contents10 sections
Key Takeaways
- Immediate effect: RDC 982/2025 took effect July 29, 2025, establishing risk-based criteria for GMP and GDP certification in Brazil.
- Risk stratification: Manufacturing sites are categorized by risk profile, allowing ANVISA to prioritize inspection resources on higher-risk facilities while reducing burden on consistently compliant low-risk sites.
- International alignment: The framework harmonizes with ICH Q9 and PIC/S standards, facilitating global regulatory convergence and market access.
- Broad scope: Covers APIs, medicinal products, cannabis products, biologicals, and medical devices for both initial certification and renewals.
- AI integration: Allows artificial intelligence tools for risk analysis when meeting technical standards for validation and data protection.
What Changed Under RDC 982/2025?
ANVISA's RDC 982/2025 fundamentally transforms pharmaceutical manufacturing oversight in Brazil. The resolution, published in the Federal Official Gazette on July 28, 2025, replaces the previous one-size-fits-all inspection model with a dynamic, risk-based approach.
Under the old system, ANVISA applied relatively uniform inspection intervals regardless of a facility's compliance history or inherent risk factors. The new framework categorizes establishments based on multiple criteria: product type (APIs carry different risks than finished formulations), manufacturing complexity, historical compliance data, and results from equivalent foreign regulatory authority (EFRA) inspections.
The resolution explicitly incorporates ICH Q9 Quality Risk Management principles, requiring manufacturers to demonstrate systematic risk assessment capabilities. This includes proactive identification of potential quality issues, evidence-based decision-making, and continuous monitoring of risk controls.
How Does Risk-Based Inspection Work?
The risk-based inspection system operates through a structured evaluation process. ANVISA assigns risk scores based on health risk factors including product criticality, patient population vulnerability, and manufacturing process complexity. Facilities demonstrating consistent compliance over time may qualify for extended inspection intervals, while those with identified risks receive prioritized oversight.
Key components of the new system include:
- Risk analysis: Systematic evaluation using ICH Q9 methodology to identify and quantify quality risks
- EFRA reports: Recognition of inspection reports from equivalent foreign regulatory authorities to avoid duplication
- Continuous monitoring: Ongoing compliance surveillance based on risk management criteria rather than calendar-based schedules
- AI-assisted evaluation: Permitted use of validated artificial intelligence for risk data analysis and pattern detection
Certificates may be revoked if irregularities or risks are identified, maintaining ANVISA's enforcement authority while focusing resources on genuine risk areas.
What Products Does the Resolution Cover?
RDC 982/2025 applies broadly across the pharmaceutical supply chain. The resolution governs certification for:
| Product Category | Certificate Type | Risk Considerations |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | CBPF | High - foundation of drug quality |
| Medicinal products | CBPF / CBPDA | Variable by therapeutic area |
| Cannabis products for medicinal use | CBPF | High - controlled substance |
| Biological products | CBPF | High - complex manufacturing |
| Medical devices | CBPF | Variable by risk class |
Both initial certification and renewal processes fall under the new risk-based framework. Manufacturers must demonstrate compliance with Good Manufacturing Practices (GMP) for production facilities and Good Distribution Practices (GDP) for storage and distribution operations.
Why Does International Alignment Matter?
ANVISA's adoption of ICH Q9 and PIC/S standards affects global pharmaceutical trade. Brazil is the largest drug market in Latin America, with major manufacturing serving domestic and export markets.
Harmonization with international standards facilitates:
- Mutual recognition: Potential for agreements with PIC/S member countries to accept each other's GMP certifications
- Reduced redundancy: Recognition of EFRA inspection reports eliminates duplicate inspections
- Market access: Brazilian manufacturers gain competitive advantage in regulated export markets
- Foreign investment: Multinational companies benefit from predictable, globally aligned regulatory requirements
ANVISA's participation in international harmonization initiatives, including consultations on EU Pharmaceutical Quality System revisions incorporating ICH Q9(R1) updates, demonstrates ongoing commitment to regulatory convergence.
What Should Manufacturers Do to Prepare?
Pharmaceutical manufacturers operating in Brazil should take proactive steps to align with RDC 982/2025 requirements. The transition demands more than procedural updates—it requires embedding quality risk management into organizational culture.
Critical preparation steps include:
- Implement ICH Q9-compliant quality risk management systems with documented risk assessment methodologies
- Establish comprehensive compliance history tracking and corrective action management
- Evaluate digital quality management systems to support risk data collection and analysis
- Train personnel on risk-based thinking and evidence-based decision-making
- Prepare for potential EFRA inspection report submissions to support risk categorization
Companies with strong quality systems may find the transition straightforward. Those using reactive compliance approaches face greater challenges.
What Is the Industry Impact?
The risk-based inspection program optimizes regulatory resource allocation while maintaining safety standards. For the Brazilian pharmaceutical sector, this translates to reduced regulatory burden for consistently compliant manufacturers and more targeted oversight where risks exist.
Industry analysts note that ANVISA's approach mirrors successful implementations by FDA, EMA, and Health Canada, suggesting positive outcomes for regulatory efficiency. The framework may reduce inspection-related delays for low-risk facilities while ensuring high-risk sites receive appropriate scrutiny.
Manufacturers should monitor ANVISA guidance documents and public consultations for implementation details. The agency continues refining risk criteria and inspection protocols based on early implementation experience.
Frequently Asked Questions
What is ANVISA RDC 982/2025 and when does it take effect?
ANVISA RDC 982/2025 establishes risk-based criteria for Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) certification in Brazil. Published on July 28, 2025, it took effect immediately on July 29, 2025, replacing the previous uniform inspection model with a risk-tiered approach.
How does the risk-based inspection system reduce regulatory burden?
The system categorizes manufacturing sites by risk profile, allowing ANVISA to prioritize inspection resources on higher-risk facilities. Low-risk sites with consistent compliance histories may see reduced inspection frequency, while high-risk sites receive more intensive oversight.
Which international standards does ANVISA's new system align with?
ANVISA's RDC 982/2025 aligns with ICH Q9 (Quality Risk Management) guidelines and PIC/S (Pharmaceutical Inspection Co-operation Scheme) standards. This harmonization facilitates mutual recognition agreements and streamlines market access for Brazilian manufacturers exporting globally.
What products are covered under RDC 982/2025?
The resolution covers active pharmaceutical ingredients (APIs), medicinal products, cannabis products for medicinal purposes, biological products, and medical devices. Certification applies to both initial granting and renewal of GMP and GDP certificates.
How can manufacturers prepare for risk-based inspections?
Manufacturers should implement thorough quality risk management systems per ICH Q9, maintain clear documentation of compliance history, and consider digital quality management systems. Proactive risk assessment and corrective action tracking help achieve favorable risk categorization.
Related Coverage
- ANVISA Risk-Based Inspection: GMP Compliance Guide
- ANVISA Risk-Based Inspection: Compliance System Overview
- ANVISA Approves MagicTouch SCB for CAD
- Latin America Regulatory Updates
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
